ATX-MS-1467: Completed Phase I enrollment

Apitope completed enrollment of an open-label, international Phase I trial evaluating 5 dose levels of intradermal and subcutaneous ATX-MS-1467 every 2 weeks for 16 weeks in about 40 patients. The adm...